ArticleFrontiers in microbiology2019
The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-Resistant
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Candesartan cilexetil disrupts methicillin-resistant Staphylococcus aureus membrane and potentiates gentamicin and polymyxin B activity.Nature communications · 2026Article
- Editorial: Mechanisms and innovations in combating intracellular infections.Frontiers in microbiology · 2026Article
- Article
- Characterization of the antagonistic secondary metabolites ofFrontiers in microbiology · 2025Article
- High-throughput screening strategies for space-based radiation countermeasure discovery.Life sciences in space research · 2022Review
- The promising anti-virulence activity of candesartan, domperidone, and miconazole on Staphylococcus aureus.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- Impeding Virulence of Candida albicans by Candesartan and Domperidone.Current microbiology · 2021Article
- Antifungal Activity of the Phenolic Compounds Ellagic Acid (EA) and Caffeic Acid Phenethyl Ester (CAPE) against Drug-ResistantJournal of fungi (Basel, Switzerland) · 2021Article
- Exploring the Antivirulence Activity of Pulverulentone A, a Phloroglucinol-Derivative fromAntibiotics (Basel, Switzerland) · 2021Article
- Novel Cecropin-4 Derived Peptides against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Screening and Identification of a Novel Anti-tuberculosis Compound That Targets Deoxyuridine 5'-Triphosphate Nucleotidohydrolase.Frontiers in microbiology · 2021Article
- Anti-MRSA agent discovery using Caenorhabditis elegans-based high-throughput screening.Journal of microbiology (Seoul, Korea) · 2020Review
- The Postbiotic Activity ofFrontiers in cellular and infection microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Antimicrobial drug discovery against drug-resistant bacteria is an urgent need. Beyond agents with direct antibacterial activity, anti-virulent molecules may also be viable compounds to defend against bacterial pathogenesis. Using a high throughput screen (HTS) that utilized
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.